1 / 14

Brian Tiffee Taimur Khan Natasha Brandt Stephen Rogan

Brian Tiffee Taimur Khan Natasha Brandt Stephen Rogan. Brandon Pomerenke Jimmy Williams John Quisenberry Matthew Olszewski. Major Segments.

kerryn
Download Presentation

Brian Tiffee Taimur Khan Natasha Brandt Stephen Rogan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Brian Tiffee Taimur Khan Natasha Brandt Stephen Rogan Brandon Pomerenke Jimmy Williams John Quisenberry Matthew Olszewski

  2. Major Segments The U.S. pharmaceutical industry is defined by the census as companies engaged in researching, developing, manufacturing, and marketing drugs and biologicals for human or veterinary use.

  3. Generic vs Branded

  4. Generic vs Branded

  5. US Market Size • The world’s largest pharmaceutical market. • Estimated at $300 billion in 2009 • Growth has decreased due to an increase in the number of drugs losing patent protection • U.S. generic drug market is estimated at $34 billion (41% of global sales)

  6. US Industry Leaders

  7. GlobalIndustry Leaders

  8. In the Beginning • “Under the DESI (Drug Efficacy Study Implementation), the National Research Council was able to assess over 3000 products • The review allowed drug makers to apply for approval of “similar” generic drugs without bio-testing • Giving way to Generic Pharmaceuticals • The Hatch-Waxman Act of 1984 was passed allowing the Food and Drug Administration to approve generic drugs for sale

  9. Future:Patent Cliff 29.4 The Patent Cliff is an event in which a large number of patents lose their protection and become available to Generic Pharmaceuticals. At the end of 2011, roughly 30 billion dollars lost their patent protection. (US) Billions 12.9 12.5 6.4 6.2 2.2 2012 2016 2017 2013 2015 2014

  10. Mylan v. Sanofi • Founded in US • Revenue- $4.99 Billion • +12% growth over 2011 • Located in 150 countries • Has the largest generic pipeline worldwide • Founded in France • Revenue- $2.03 Billion • +15% growth over 2011 • Located in 100 countries • Offers the broadest range of vaccines

  11. Industry Past • Has experienced rapid growth • Saved US healthcare $1.07 Trillion in the past decade (2002-2011)

  12. Industry Future • In 2016, patents worth over $40 billion dollars in US sales will lose patenting protection • This will give the industry access to a wide range of drugs previously unreachable

  13. Present Ind. • In 2011Generic Pharmaceuticals filled 80% of the prescriptions in the US • Yet consumed only 27% of total drug spending

  14. Industry Future • Many of the highest grossing brand name drugs lost patent-protection between 2011-2012, leading to an estimated loss of $140 billion to generic competition by 2017

More Related